Age moderates the relationship between psychedelics use and mental health in naturalistic settings
Giammarco di Gregorio, Sophia Basset, Harjot Manmohan, Warren C. Nixon, Amrutha Pogaku, Jing Zhou, David J. Sanderson, Michael L. Lengieza, Marco Bocchio
Research Square March 10, 2026 preprint DOI: 10.21203/rs.3.rs-9022170/v1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey |
|---|---|
| Sample size | 1,088 |
| Population | Adults aged 18–55+ years |
| Topics | Anxiety |
| Keywords | Mental health Moderation Depression economics Naturalistic observation Affect linguistics Clinical psychology |
| Key findings | Age significantly moderates the relationship between psychedelic use and mental health: classic psychedelic use was linked to lower depression and anxiety in younger adults, but these effects diminished with age and reversed for anxiety in older participants. |
Abstract
Abstract Depression and anxiety affect one in five adults, with age affecting prevalence. While clinical trials suggest classic psychedelics (e.g., psilocybin, LSD) and non-classic psychedelics (e.g., MDMA, ketamine) may alleviate these symptoms, it remains unclear how these relationships function in naturalistic settings or how they vary across the lifespan. We conducted a cross-sectional survey of 1,088 adults (18–55 + years) to assess how lifetime psychedelic use - categorized as classic, non-classic, or mixed - relates to mental health. Using structural equation modeling, we found that age significantly moderates the relationship between psychedelic use and mental health outcomes. Specifically, classic psychedelic use was linked to lower depression and anxiety among younger adults, but these effects diminished with age - even reversing for anxiety in older participants. These age-related effects persisted independently of drug-use parameters - including dosage, frequency, and recency of use - and were moderated by mystical experiences for depression, but not for anxiety. Our findings suggest that age may be a meaningful moderator of mental health outcomes from psychedelic use. This underscores the potential value of age-stratified research to optimize the efficacy and safety of psychedelic-assisted interventions, including in aging populations.
Comparable studies
Other cross-sectional and survey studies on anxiety, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. International sample of people who reported having used a psychedelic | 2020 | Cross-sectional survey | n = 985 |
| The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms Internet survey respondents reporting challenging experiences with psilocybin | 2016 | Questionnaire development and validation | |
| Psychedelics and Mental Health: A Population Study Adult population in the United States | 2013 | Cross-sectional survey | n = 130,152 |
| Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users Ecstasy users who participated in a WWW study of recreational drug use | 2002 | Cross-sectional survey | n = 282 |
| 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Adults who used 5-MeO-DMT in a group setting with structured procedures | 2019 | Cross-sectional survey | n = 362 |
Citations in the library
Cites 26
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
and 21 more in the library